Compare Amphastar Pharmaceuticals Inc (AMPH) vs Broadcom Inc (AVGO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Broadcom Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Broadcom Inc trades at $393.99 (market cap $1.90T). The key difference: Broadcom Inc is far larger — about 2300× Amphastar Pharmaceuticals Inc's market cap, and Broadcom Inc pays a 0.65% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | AVGO | |
|---|---|---|
Market Cap | $826.08M | $1.90T |
Sector | Health | Technology |
52-Week High | $30.81 | $481.57 |
52-Week Low | $16.87 | $274.38 |
Enterprise Value | $1.22B | $1.95T |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Broadcom (AVGO) trades at $399.97, down 0.28% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $2.44 versus $2.40, continuing a pattern of earnings outperformance. Recent news highlights a significant $30 billion Apple chip supply deal extending through 2031, providing substantial revenue visibility for its custom AI silicon operations.
Broadcom presents a compelling growth story driven by AI semiconductor demand and strategic partnerships, with analyst consensus strongly bullish (86% buy ratings) and a $510.43 price target suggesting 28% upside. Key risks include high valuation multiples (P/E 66.55) and dependence on major customers like Apple, though strong cash flow generation ($27.54B operating cash flow in 2025) supports dividend payments and debt reduction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →
